Great news from our partners at #Oragenics! Enrollment is now complete for their phase 2 clinical trial of AG013 for #oralmucositis. AG013 is an ActoBio Therapeutics Inc. candidate created on our #ActoBiotics® platform and licensed to Oragenics. More: http://actobio.com pic.twitter.com/PJ0V9inbEX
07:19 - 2. pro 2019.
0 replies
4 proslijeđena tweeta
12 korisnika označava da im se sviđa
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.